Giovanni Spagnolli

Giovanni Spagnolli earned a Master’s degree in Cellular and Molecular Biotechnology (110/110 Cum Laude) and a Ph.D. in Biomolecular Sciences (Best Ph.D. student, CIBIO 33rd Cycle) at the University of Trento. During his doctoral research, he worked on developing and validating the PPI-FIT technology by applying it to the cellular prion protein. This study led to the discovery of the first small molecule degrader acting by targeting a protein folding intermediate. Concurrently, he worked on applying enhanced sampling molecular dynamics simulation techniques to achieve atomic-level characterization of the prion propagation mechanism. His thesis work and additional contributions to different multidisciplinary projects were acknowledged in more than 10 peer-reviewed publications, including research articles, reviews, and a book chapter.
As CTO of Sibylla Biotech, Giovanni leads the R&D and pipeline activities of the company. He is also involved in the company fundraising and playeed a key role in the raise of the latest € 23M Series A round.